Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., March 02, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors...
February 24, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)

RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new long-term efficacy and safety data from the APeX-2 clinical trial...
February 23, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones

— Q4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021 — — ORLADEYO net revenue in 2022 expected to be no less than $250 million — — Pivotal trials in PNH and...
February 22, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases

RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the RENEW proof-of-concept basket...
February 09, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Report Fourth Quarter 2021 Financial Results on February 23

RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2021...
February 08, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Appoints Machelle Sanders to Board of Directors

RESEARCH TRIANGLE PARK, N.C., Feb. 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed North Carolina Secretary of Commerce, and...
February 03, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
February 01, 2022 09:25 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present three abstracts featuring new data on...
January 10, 2022 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Announces Preliminary Full Year 2021 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance

—ORLADEYO preliminary net revenue of $45.6 million for Q4 2021 and $122 million for FY 2021— —ORLADEYO net revenue expected to more than double in 2022 to no less than $250 million; Company expects...
January 07, 2022 09:25 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH

RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-1 pivotal trial with...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right